Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thermal stability of p53 is crucial in preventing cancer proliferation. Critical mutations which significantly destabilize p53 conformation prevent normal interaction between p53 and DNA and consequently interfere with its inhibitory function against cancer proliferation. The purpose of this study was to discover the small compounds called 'chemical chaperons' that can efficiently stabilize the functional p53 conformation and restore the anti-cancer activity. To search for such compounds, we performed a docking simulation using the AutoDock program and the ZINC database. Simply based on the docking energy, we extracted 70 compounds (GJC1-GJC70) and examined their anti-cancer activity using the MTT assay of the human colon cancer cells, HCT116. We found that two compounds, GJC29 and GJC30, significantly inhibited the proliferation of cancer cells compared to the positive control staurosporine. Interaction between p53 and novel anti-cancer compounds were confirmed using SPR measurements. Intriguingly, in the simulated binding mode, both compounds bind to the pocket in the vicinity of the residue V143, one of the mutation hot-spots in p53. Finally, we injected each compound subcutaneously into the nude mice implanted with HCT116 and found that GJC29 has a strong suppressive effect against cancer proliferation in vivo. In conclusion, p53 is an appropriate target for the rational design of the chemical chaperon for cancer treatment.
 ...
PMID:Novel anti-cancer compounds: structure-based discovery of chemical chaperons for p53. 1972 51

Gap junctions are specialized plasma membrane domains consisting of channels formed by members of the connexin protein family. Gap junctional intercellular communication is often lost in cancers due to aberrant localization or downregulation of connexins, and connexins are therefore suggested to act as tumor suppressor genes in various tissues. The aim of this study was to investigate the expression pattern and DNA promoter methylation status of connexins in colorectal cancer. Expression of six (GJA1, GJA9, GJB1, GJB2, GJC1 and GJD3) connexin genes was detected in normal colonic tissue samples. GJC1 expression was reduced in colorectal carcinomas compared to normal tissue samples. All analyzed connexins were hypermethylated in colon cancer cell lines, although at various frequencies. GJA4, GJB6 and GJD2 were hypermethylated in 60% (29/48), 25% (12/48) and 96% (46/48) of primary colorectal carcinomas, respectively. However, the methylation status was not associated with gene expression. GJC1 has two alternative promoters, which were methylated in 42% (32/76) and 38% (25/65) of colorectal tumors, and in none of the normal mucosa samples. Expression of GJC1 was significantly lower in methylated compared with unmethylated samples (p < 0.01) and was restored in cell lines treated with the demethylating drug 5-aza-2'deoxycytidine. Taken together, DNA hypermethylation of the promoter region of GJC1, encoding connexin45, is an important mechanism in silencing gene expression in colorectal cancer.
 ...
PMID:DNA methylation analyses of the connexin gene family reveal silencing of GJC1 (Connexin45) by promoter hypermethylation in colorectal cancer. 2140 65